Updated Practice Guideline for Somatostatin Receptor Scintigraphy

Balon, Helena

doi:10.2967/jnumed.111.098285

Cited by 26 publications

(29 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because not all insulinomas express somatostatin receptor type 2, 111In-pentetreotide scintigraphy is positive in only 46% of benign insulinomas [52,53]. Just to the right of the insulinoma is the portal vein (white with "tail"-vein from the spleen joining it) carrying blood from intestine and pancreas to liver [42].…”

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

Insulinoma: Literature’s Review (2)

AlJadir¹

2015

EMIJ

View full text Add to dashboard Cite

Section: Somatostatin Receptor Scintigraphymentioning

confidence: 99%

Insulinoma: Literature’s Review (2)

AlJadir¹

2015

EMIJ

View full text Add to dashboard Cite

“…Physiological uptake of radiolabelled SSAs occurs in pituitary, thyroid, kidneys, liver and spleen (18). Falsepositive SRS in GEP-NETs might occur in patients with accessory spleen(s), infections, adrenal medullary tumours and sometimes in the uncinate process of the pancreas (13).…”

mentioning

confidence: 99%

“…Planar and single-photon emission CT (SPECT) images are generally obtained 24 and 48 h after injection of this radiopharmaceutical (2,18,19). For a detailed protocol, the reader is referred to the literature (18,19). The reported overall sensitivity of SRS for well-differentiated (grades 1 and 2) GEP-NETs is also more than 80%.…”

mentioning

confidence: 99%

“…The sensitivity of SRS is generally lower in: † Small tumours with a diameter generally !1 cm, due to insufficient tumour-to-background uptake ratios of radioactivity (13); † non-metastasised insulinomas (sensitivity !50%), reflecting the generally low sst 2(a) expression in this specific group of benign pancreatic NETs (13,24); and † NETs or neuroendocrine carcinomas (NECs) with a high Ki-67 index, reflecting dedifferentiation and loss of ssts; in these cases, 18 F-fluorodeoxy-D-glucose ( 18 F-FDG) positron emission tomography (PET) might be a better option for total body imaging (see below) (25). PET: PET/CT using 68 Ga-DOTA-labelled SSAs…”

mentioning

confidence: 99%

“…This radiopharmaceutical preferentially binds to sst 2(a) and with decreasing lower affinities to also sst 5 and sst 3 (2,14,17). Planar and single-photon emission CT (SPECT) images are generally obtained 24 and 48 h after injection of this radiopharmaceutical (2,18,19). For a detailed protocol, the reader is referred to the literature (18,19).…”

mentioning

confidence: 99%

See 2 more Smart Citations

GEP-NETs update: Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs)

Herder¹

2014

European Journal of Endocrinology

View full text Add to dashboard Cite

For patients with neuroendocrine tumours (NETs) of the gastrointestinal tract and pancreas (GEP) (GEP-NETs), excellent care should ideally be provided by a multidisciplinary team of skilled health care professionals. In these patients, a combination of nuclear medicine imaging and conventional radiological imaging techniques is usually mandatory for primary tumour visualisation, tumour staging and evaluation of treatment. In specific cases, as in patients with occult insulinomas, sampling procedures can provide a clue as to where to localise the insulin-hypersecreting pancreatic NETs. Recent developments in these fields have led to an increase in the detection rate of primary GEP-NETs and their metastatic deposits. Radiopharmaceuticals targeted at specific tumour cell properties and processes can be used to provide sensitive and specific whole-body imaging. Functional imaging also allows for patient selection for receptor-based therapies and prediction of the efficacy of such therapies. Positron emission tomography/computed tomography (CT) and single-photon emission CT/CT are used to map functional images with anatomical localisations. As a result, tumour imaging and tumour follow-up strategies can be optimised for every individual GEP-NET patient. In some cases, functional imaging might give indications with regard to future tumour behaviour and prognosis.

show abstract